Virtual screening and experimental validation of novel histone deacetylase inhibitors by Yan-xin Huang et al.
RESEARCH ARTICLE Open Access
Virtual screening and experimental
validation of novel histone deacetylase
inhibitors
Yan-xin Huang1* , Jian Zhao1†, Qiu-hang Song1†, Li-hua Zheng1, Cong Fan1, Ting-ting Liu1, Yong-li Bao1,
Lu-guo Sun1, Li-biao Zhang2* and Yu-xin Li3*
Abstract
Background: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes
and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great
deal of interest for both research and clinical applications. Increasing efforts have been focused on the discovery of
HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy. However, most HDAC
inhibitors, including the clinically approved agents, do not selectively inhibit the deacetylase activity of class I and II
HDAC isforms, and many suffer from metabolic instability. This study aims to identify new HDAC inhibitors by using
a high-throughput virtual screening approach.
Methods: An integration of in silico virtual screening and in vitro experimental validation was used to identify novel
HDAC inhibitors from a chemical database.
Results: A virtual screening workflow for HDAC inhibitors were created by integrating ligand- and receptor- based
virtual screening methods. Using the virtual screening workflow, 22 hit compounds were selected and further
tested via in vitro assays. Enzyme inhibition assays showed that three of the 22 compounds had HDAC
inhibitory properties. Among these three compounds, ZINC12555961 significantly inhibited HDAC activity.
Further in vitro experiments indicated that ZINC12555961 can selectively inhibit proliferation and promote
apoptosis of cancer cells.
Conclusions: In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC
inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines. These results
suggest that the developed virtual screening workflow can provide a useful source of information for the
screening and validation of new HDAC inhibitors. The new-found HDAC inhibitors are worthy to further and
more comprehensive investigations.
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Background
The dynamic post-translational modification of nucleo-
somal histones plays a critical role in transcriptional
regulation. Hyperacetylation of nucleosomal core his-
tones results in transcriptional activation, while their
hypoacetylation leads to transcriptional repression. Mod-
ifications of nucleosomal histone acetylation and deace-
tylation affect the chromatin structure and related gene
expression, and thus regulate various cellular processes,
including DNA synthesis, cell division and differenti-
ation, apoptosis, and others [1, 2]. The level of histone
acetylation is determined by histone acetyltransferase
(HAT) and histone deacetylase (HDAC) activities [3, 4].
Impaired HDAC activity could interfere with the balance
between HATs and HDACs and thus alter the transcrip-
tional status of many genes, in particular those related
to disease. Therefore, HDACs have become promising
therapeutic targets for the treatment of cancer, diabetes,
and other human diseases [5, 6]. HDACs are classified
into four classes (Classes I–IV) depending on their se-
quence identity and domain organization. Classes I
(HDACs 1–3 and 8), II (HDACs 4–7, 9, and 10), and IV
(HDAC 11) are referred to as classical HDACs and are
generally simultaneously targeted by most HDAC inhibi-
tors [7]. Class III HDACs include Sirt1–7; they are
nicotinamide (NAD)-dependent and are insensitive to
HDAC inhibitors [8]. To date, a number of HDAC in-
hibitors have been reported and they can be divided into
several structural categories: hydroxamic acids, aliphatic
acids, benzamides, cyclic peptides and others [9–11].
HDAC inhibitors have emerged as a new class of
therapeutic agents and have generated much interest
among pharmacologists, and cancer and diabetes re-
searchers [5, 12, 13]. Three HDAC inhibitors, vorino-
stat (SAHA) [14], cyclic peptide FK228 (romidepsin)
[15, 16] and belinostat [17], have been approved by
the U.S. Food and Drug Administration (FDA) for the
treatment of cutaneous and peripheral T cell lymph-
oma. However, most HDAC inhibitors, including the
clinically approved agents, non-selectively inhibit the dea-
cetylase activity of class I and II HDACs, and many suffer
from metabolic instability. These characteristics have been
associated with reduced potency and toxic side effects in
vivo [18]. Significant efforts are ongoing to address these
and other deficiencies of HDAC inhibitors to improve
their HDAC inhibitory potential for the treatment of can-
cer and other diseases [19–21]. In addition, substantial ef-
forts have been made to develop new HDAC inhibitors
with potential therapeutic applications [22]. In the present
study, we present a hierarchical virtual screening protocol
with SYBYL-X2.0 [23] and Gold 5.2 [24] software suites
for the identification of compounds as potential HDAC
inhibitors. It provides a stable and reliable solution for vir-
tual screening of HDAC inhibitors based on commercial
software’s of drug discovery. A pharmacophore model
was built and used for virtual screening to identify can-
didate compounds from the enamine dataset in the
ZINC database [25]. Then, the remaining compounds
were docked into the active site of HDAC8. Finally, 22
compounds were identified as the final hit compounds.
Enzyme inhibition assays with the HDAC inhibitor
drug screening kit showed that three of the 22 com-
pounds had HDAC inhibitory properties. Among these
three compounds, ZINC12555961 was confirmed to
have significant inhibitory activity against HDACs. Fur-
ther in vitro cell experiments demonstrated that
ZINC12555961 can selectively inhibit proliferation and
promote apoptosis of cancer cells.
Methods
Pharmacophore modeling
The GALAHAD module in SYBYL-X 2.0 was adopted
for ligand-based pharmacophore modeling. Seven hydro-
xamic acid inhibitors (marked with * in Table 1) with
structural diversity were selected as representative com-
pounds. All parameters were set to their default values
(such as aligning molecules with pharmacophore fea-
tures, no molecular template used, etc.) with the excep-
tion of 150 generations and a population size of 100. In
the virtual screening process performed with the UNITY
module in SYBYL-X2.0, at least five out of seven features
in the pharmacophore model had to be matched.
Molecular docking
GOLD 5.2 was adopted for molecular docking screening.
HDAC8 (PDB id: 1 T69) was selected as the docking tar-
get. All the water molecules in HDAC8 were removed
and hydrogen atoms were added. The binding site of
HDAC8 was defined as those residues within 10 Å from
the ligand in the X-ray structures. The parameters of the
genetic algorithm (GA) were used in default values (such
as the population size of 100, the selection pressure of
1.1, etc.) except that ligands were subjected to 30 GA
runs, the number of operations was set to 300,000, and
the early termination option was turned off. The three
top scoring conformations of every ligand were retained
at the end of the calculation. Two of the fitness func-
tions implemented in GOLD 5.2, ChemPLP and Chem-
Score were used in our experiments.
HDAC inhibitory activity assay
The HDAC inhibitor drug screening kit (k340-100, Bio-
Vision, CA, USA) was used to measure HDAC inhibi-
tory activities of the candidate compounds according to
the manufacturer’s instructions. The candidate com-
pounds, assay buffer, and HDAC fluorometric substrate,
which comprises an acetylated lysine side chain, were
added to HeLa nuclear extracts in a 96-well plate and
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incubated at 37 °C for 30 min. The reaction was stopped
by adding lysine developer, and the mixture was incu-
bated for another 30 min at 37 °C. An additional positive
control included incubation with double-distilled water,
and the inhibitor control consisted of incubation with
Trichostatin A (TSA) at 20 μM. HDAC activities were
quantified by a fluorescence plate reader (POLARstar
OPTIMA, BMG, BRD) with excitation at 370 nm and
emission at 450 nm.
Cell lines
Four cell lines, namely HepG2 (human hepatocellular car-
cinoma cell line), L02 (human normal liver cell line),
MDA-MB-231 (human breast cancer cell line), and MCF-
10A (human normal breast cell line), were obtained from
the Cell Bank of the Chinese Academy of Sciences (Shang-
hai, China). Cells were cultured in an appropriate medium
supplemented with 10 % fetal bovine serum (TBD Science,
Tianjin, China), 100U/ml penicillin and 100 mg/mL
streptomycin (Ameresco, US) at 37 °C and 5 % CO2.
MTT assay
The MTT (3-(4, 5-dimethylthia-zol-2-yl)-2, 5-diphenyl
tetrazolium bromide) assay was used to examine the ef-
fects of the candidate compounds on cell viability. The
candidate compounds were dissolved in DMSO (di-
methyl sulfoxide) as 10 mM/L stock solutions. Cells
were plated in 96-well plates (1 × 104 cells/well) in
100 μL of growth medium and allowed to grow for 24 h.
The cells were then treated with 0, 1, 10, 50 and 100 μM
of each candidate compound in the presence of 3 %
serum. After 44 h of treatment, 20 μL of MTT [5 mg/
mL in phosphate-buffered saline (PBS); Sigma Chemical
Co.] were added to each well for an additional 4 h of in-
cubation. The blue MTT formazan precipitate was dis-
solved in 100 μL of DMSO. The optical density of
samples was measured at 570 nm using a micro ELISA
reader (Bio-Rad, Hercules, CA). Cell viability was
expressed as a percentage relative to the untreated con-
trol cells.
DAPI staining assay
A DAPI staining assay was performed to reveal the pres-
ence of condensing nuclei and apoptotic bodies in
compound-treated cells. HepG2 and MDA-MB-231 cells
were treated with the candidate compounds (60 and
90 μM) for 48 h, and then harvested, fixed with 4 %
paraformaldehyde for 30 min, washed with PBS, and
stained with DAPI at a final concentration of 0.5 μg/mL
for 15 min at room temperature. The cells were then
analyzed using a fluorescence microscope. Three inde-
pendent experiments were performed, and at least four
different fields with a minimum of 100 cells/field were
scored.
Apoptosis assay
Annexin V-FITC/PI (propidium iodide) assay was per-
formed to evaluate apoptosis of cancer cells induced by
the hit compound ZINC12555961. HepG2 and MDA-
MB-231 cells were seeded on 6-well plates at a density
of 1 × 106 cells/well, and incubated with 90 μM of
ZINC12555961 for 48 h. Then, the cells were harvested
by trypsinization, washed in ice-cold PBS, and resus-
pended in 190 μL binding buffer containing 5 μL
Annexin V and 10 μL PI (Beyotime, China). The cells
were incubated in the dark for 10 min and then analyzed
by flow cytometry (BD FACSCanto™).








SAHA [31, 46, 47]
TSA [31, 47]
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Cell cycle analysis
DNA staining with PI (Beyotime, China) was used to de-
termine the cell cycle distribution of compound-treated
cells. The number of cells at specific phases of the cell
cycle was analyzed and sorted using flow cytometry.
HepG2 and MDA-MB-231 cells were seeded at a density
of 1 × 106 cells/well. After treatment, the cells were col-
lected, washed with PBS, fixed with 50 % alcohol and
stained with PI at a final concentration of 1 mg/mL for
30 min. The percentages of cells in different phases of
the cell cycle were measured with a flow cytometer (BD
FACSCantoTM) and analyzed with the Modfit software
(Verity Software House, Topsham, USA).
Results
Pharmacophore-based virtual screening
The Enamine dataset in the ZINC database, containing
collection of 1.8 million structurally diverse compounds,
were used as the screening compound set [25]. As listed
in Table 1, seven compounds were used to generate
pharmacophore models. 50 hydroxamic acid-based
HDAC inhibitors collected from the literature [26–31]
and Enamine_p0.18, a subset of the enamine dataset
[25], which contains 22,565 compounds, were combined
as the test dataset. Moreover, the maximal unbiased
benchmarking data sets for HDACs (MUBD-HDACs)
that cover all classical HDACs, composed of 631 HDAC
inhibitors and 24,609 unbiased decoys [32], were further
used to validate our pharmacophore models. The HDAC
inhibitor data sets in MUBD-HDACs have been vali-
dated extensively as chemically diverse, while the decoy
sets are shown to be property-matching with ligands but
have no HDAC inhibitory activities. MUBD-HDACs is
freely available at http://www.xswlab.org/. All com-
pounds were minimized under the Tripos Standard (TS)
force field with Gasteiger-Hückel atomic partial charges.
Minimizations were done using the Powell method and
terminated at an energy gradient value of 0.01 kcal/mol.
All models derived from at least six ligands of the train-
ing set (N_NITS ≥ 6) are listed in Table 2, except those
models with high energies. Constructing a good pharma-
cophore model requires balancing among various criteria
such as maximizing steric consensus (STERICS), maxi-
mizing the pharmacophore consensus (HBOND), and
minimizing strain energy (ENERGY) [33]. SPECIFICITY
is a logarithmic indicator of the expected discrimination
for each model. It is based on the number of features con-
tained, their distribution across any partial match con-
straints, and the degree to which the features are
separated in space. A good pharmacophore model usually
has a higher SPECIFICITY value, a higher steric score and
a lower energy value. MODEL_001, MODEL_002,
MODEL_005, MODEL_006, MODEL_010, MODEL_021,
MODEL_030, and MODEL_041 were selected to further
validate their screening abilities for the test dataset and
the decoy dataset. The enrichment factor (EF) was calcu-
lated using equation (1):
EF ¼ Ha Dð Þ = Ht  Að Þ ð1Þ
Where D indicates the total number of compounds in
the test datasets; A means the total number of known
inhibitors in the test datasets; Ht is the hit number of
compounds retrieved from the test datasets; and Ha rep-
resents the number of known inhibitors in the hit
compounds.
As listed in Table 3, the calculation results indicated
that MODEL_006 had the best EF values. Moreover,
MODEL_006 had the highest SPECIFICITY value, a
moderate steric score, and an acceptable energy value.
Therefore, it was selected as the final pharmacophore
model. As shown in Fig. 1, MODEL_006 included seven
pharmacophore features as follows: three hydrophobes
(HY5, HY6 and HY7), two hydrogen bond (HB) accep-
tors (AA3 and AA4), and two HB donors (DA1 and
DA2). Note that the pharmacophore AA_4 and DA_2
were overlapped each other. The hydrophobic moieties
of the pharmacophore reflect the need for a hydrophobic
Table 2 Pharmacophore models generated by GALAHAD
Name SPECIFICITY N_NITS ENERGY STERICS HBOND
MODEL_001 2.762 6 59.04 1807.4 255.3
MODEL_002 2.321 7 44.53 1724.8 240.0
MODEL_005 3.842 6 42.64 1585.6 241.8
MODEL_006 5.225 6 55.97 1822.2 239.9
MODEL_010 2.208 7 48.49 1714.7 243.7
MODEL_021 4.220 6 42.25 1551.0 224.6
MODEL_030 2.821 6 44.05 1610.4 231.5
MODEL_035 1.094 6 40.95 1630.8 235.7
MODEL_037 1.651 6 44.93 1714.6 233.4
MODEL_041 2.545 6 39.68 1521.0 202.5
Table 3 The EF values of the pharmacophore models for the
test and decoy datebases
Name Test dataset Decoy dataset
Ht Ha EF Ht Ha EF
MODEL_001 235 40 76.98723 8743 398 1.82089
MODEL_002 269 36 60.53086 9586 365 1.52305
MODEL_005 145 24 74.86345 8652 403 1.86315
MODEL_006 198 43 98.22677 8752 543 2.48172
MODEL_010 227 40 79.70044 7962 412 2.06983
MODEL_021 154 28 82.23636 8965 474 2.11489
MODEL_030 178 25 63.52528 9045 387 1.71144
MODEL_041 218 38 78.84128 9654 455 1.88523
Huang et al. BMC Pharmacology and Toxicology  (2016) 17:32 Page 4 of 14
region such as the linker domain or the cap group do-
main [33]. The HB acceptor and donor moieties of the
pharmacophore reflect the need for the ZBG domain
[27]. As a result, MODEL_006 was used as a 3D query
to screen the Enamine database using the UNITY search
module in SYBYL-X 2.0. In the seven features of
MODEL_006, the maximum omitted features were set
to two. The final 11,905 hits were retrieved.
Molecular docking-based virtual screening
Initial validation of the docking protocol was performed
by re-docking the ligand extracted from the HDAC 8
crystal structure (PDB id: 1 T64) to HDAC 8 itself. The
top conformation of the ligand produced by GOLD 5.2
was very close to the crystal structure-bound conform-
ation of the ligand. The root-mean-square deviation be-
tween the docked pose and its bound pose in the crystal
structure was 0.75 Å. This indicated that GOLD 5.2 is
able to reproduce the correct binding pose of an HDAC
inhibitor ligand to its receptor. Next, the decoy dataset
MUBD-HDACs [32] were further used to validate our
docking protocol. 1 T64, 1 T67 and 1 T69 were used as
the receptor protein and the four docking functions in
GOLD 5.2 (ChemPLP, Goldscore, Chemscore and ASP)
were used as scoring functions. The EF values and func-
tional thresholds of ChemPLP, Goldscore, Chemscore
and ASP for the top 1, 5, 10 and 20 % of ranked com-
pounds in the decoy database were listed in Table 4.
From the Table 4, we can see that the EF values of
ChemPLP and Chemscore are obviously higher than that
of Goldscore and ASP. The previous literature also
pointed out that ChemPLP demonstrated the best re-
sults for both pose prediction and virtual screening [34].
So we chose ChemPLP and Chemscore together to fur-
ther evaluate their screening results. As listed in Table 5,
the combination of the two scoring functions is better in
screening results than the two separate functions. Fi-
nally, ChemPLP was chosen as the main function and
Chemscore was chosen as as the secondary scoring func-
tion for practical screening. After validation of the dock-
ing protocol, all 11,905 hits retrieved by pharmacophore
model-based screening were docked into the active site
of three crystal structures of HDAC8 (1 T64, 1 T67 and
1 T69). According to the actual situation, the about top
1 % of ranked compounds in the hit database were de-
cided to remain for experimental validation. The score
72 for ChemPLP and 23 for ChemScore were selected as
the final score thresholds. As a results, 154 compounds
Fig. 1 Pharmacophore MODEL_006 and its molecular alignment derived from the representative compounds. a Molecular alignment of 7
representative compounds. b Pharmacophore model (length unit: angstrom): three hydrophobes (HY5, HY6 and HY7), two hydrogen bond (HB)
acceptors (AA3 and AA4), and two HB donors (DA1 and DA2). Cyan spheres represent hydrophobes; green spheres indicate HB acceptors; and
magenta spheres indicate HB donors. Note that the pharmacophore AA_4 and DA_2 were overlapped each other
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were selected as the hit compounds. Finally, the Selector
module in SYBYL-X 2.0 was adopted for the clustering
analysis by creating and comparing diverse subsets of
the 154 hit compounds. 22 of the 154 hit compounds
with diverse structures were selected as the final hits
(listed in Table 6). We further examined the binding pat-
terns of the 22 final hits (Additional file 1: Figure S1). As
listed in Table 7, the binding patterns of the 22 hit com-
pounds can be divided into five types. For the first class
of compounds, their ZBG domain may form covalent
metal chelate complexes and hydrogen bond interactions
with HDAC residues. For the second class of com-
pounds, their ZBG domain and the linker domain may
form covalent metal chelate complexes and hydrogen
bond interactions with HDAC residues. For the third
class of compounds, its ZBG domain and cap group do-
main may form covalent metal chelate complexes and
hydrogen bond interactions with HDAC residues
GLY151 and TYR306. The fourth class of compounds in-
cluded ZINC03260906 and ZINC09715944. The ZBG do-
main of ZINC03260906 may form covalent metal chelate
complexes and its linker domain and the cap group do-
main may form hydrogen bond interactions with HDAC
residues HIS180 and PHE208. The ZBG domain of
ZINC09715944 may form covalent metal chelate com-
plexes and its linker domain and the cap group domain
may form hydrogen bond interactions with HDAC resi-
dues LYS33, HIS143, and SER150. The fifth class of com-
pounds included ZINC02627831 and ZINC12581173. The
linker domain of ZINC02627831 may form hydrogen
bond interactions with HDAC residue ASP101. The ZBG
domain of ZINC12581173 may form hydrogen bond in-
teractions with HDAC residue LYS33.
Inhibitory enzymatic activity evaluation
Based on the in silico results, additional in vitro studies
were performed to evaluate the activity of the final 22
hit compounds. A fluorometric HDAC activity assay was
firstly performed to examine the inhibitory activity of
the 22 hit compounds against HDACs in HeLa nuclear
extracts (Biovision K340-100). The experimental results
are depicted in Fig. 2, which shows that three com-
pounds, namely ZINC12555961, ZINC02639234, and
ZINC09715944, inhibited the enzymatic activity of
HDACs. Their relative enzymatic activities were 52 % (P
= 0.008), 76 % (P = 0.006) and 82 % (P = 0.011), respect-
ively, whereas that of the control inhibitor TSA was
12 % (P = 0.0003). The other 19 hit compounds did not
show significant inhibitory activity against HDACs.
The three active compounds did not belong to either
of the four main classes of HDAC inhibitors, namely
hydroxamic acids, aliphatic acids, benzamides, and cyclic
peptides [9–11]. ZINC12555961 has four main func-
tional groups: fluorophenyl, methoxyphenyl, acrylamide
cyanide and nitrophenyl; ZINC02639234 has three main
functional groups: benzothiazole, triazole and dihydroxy
phenyl; and ZINC09715944 has three main functional
groups: benzene and pyridazine ketone, pyrrole and
methoxypheny. The docking poses of the three active
compounds to the active site of HDAC8 (1 T69) are
shown in Fig. 3. The two hydroxyls of the dihydroxy
phenyl group of ZINC02639234 formed covalent chelate
complexes with zinc ions and hydrogen bond interac-
tions with HDAC residues ASP178 and ASP267. In
addition, the benzothiazole group of ZINC02639234 had
hydrophobic contact with HDAC residue PHE208
(Fig. 3a). For ZINC09715944, its methoxyphenyl group
formed covalent chelate complexes with zinc ions, the
carbonyl of its linker domain formed hydrogen bond in-
teractions with HDAC residue LYS33, and the carbonyl
of its benzene and pyridazine ketone group was not only
able to form hydrogen bond interactions with HDAC
Table 5 The EF values and functional thresholds for the top 1,
5, 10 and 20 % of the decoy database in combined docking
function test
Top (%) Docking functions EF
ChemPLP Chemscore 1T64 1T67 1T69
1 71.8 22.8 4.84 4.54 4.98
5 67.4 17.6 4.37 4.21 4.43
10 62.1 14.2 3.53 3.84 3.81
20 57.5 12.3 3.24 3.31 3.42
Table 4 The EF values and functional thresholds for the top 1,








ChemPLP 1 72.9 4.67 4.21 4.87
5 68.3 4.47 4.15 4.68
10 62.8 4.31 4.09 4.52
20 56.9 4.14 4.02 4.44
Goldscore 1 60.1 1.87 1.37 1.14
5 55.4 1.71 1.23 1.04
10 50.1 1.68 1.19 0.98
20 46.2 1.65 1.14 1.03
Chemscore 1 23.7 4.08 3.94 4.31
5 19.1 3.98 3.81 4.18
10 15.1 3.94 3.78 4.15
20 12.7 3.87 3.72 4.06
ASP 1 35.3 1.45 1.21 1.78
5 31.3 1.31 1.11 1.56
10 28.4 1.29 1.03 1.38
20 24.1 1.23 0.95 1.15
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residues HIS143 and SER150, but was also able to form
hydrophobic contact with HDAC residue PHE208
(Fig. 3b). For ZINC12555961, the hydroxyl of its nitro-
phenyl group was not only able to form covalent chelate
complexes with zinc ions, but was also able to form
hydrogen bond interactions with HDAC residue
ASP267; the nitro of its nitrophenyl group could form
hydrogen bond interactions with HDAC residues
GLY304, GLN263, GLY140 and HIS142; the carbonyl
group of its acrylamide cyanide was able to form hydro-
gen bond interactions with HDAC residue HIS180, and
its methoxyphenyl group was in hydrophobic contact
with HDAC residue PHE208 (Fig. 3c). The three com-
pounds were selected for further cytotoxicity assays.
Anti-proliferative activity and apoptosis-inducing
mechanism
HDAC inhibitors selectively induce cell growth arrest
and apoptosis in a wide variety of cancer cells. To test
the cytotoxicity of the three hit compounds with HDAC
inhibitory activities, MTT, DAPI staining, and Annexin V-
FITC assays were designed and performed according to
the procedures described in the Materials and methods
section. In the MTT assay, HepG2, L02, MDA-MB-231,
and MCF-10A cells were cultured in 3 % serum-
supplemented medium and treated with four different
concentrations (1, 10, 50, and 100 μM) of the three hit
compounds and SAHA. The viabilities of the four cell
lines after 48 h of treatment were measured using the
MTT assay. The IC50 values for ZINC12555961,
ZINC02639234, ZINC09715944 and SAHA against the
four cell lines were calculated and are listed in Table 8,
which shows that ZINC02639234 and ZINC09715944 ex-
hibited stronger toxicity towards normal cells than against
cancer cells, whereas ZINC12555961 showed stronger
toxicity towards cancer cells than normal cells. Increasing
ZINC12555961 concentrations (from 0 to 100 μM) led to
a steady decrease in the viability of MDA-MB-231cells
Fig. 2 Inhibitory activity of the 22 hit compounds against HDACs. The enzymatic activities of the hit compounds are expressed as percentages of
the positive control. Black bars represent the positive control, white bars represent the inhibitor control, and gray bars indicate the hit
compounds being treated. Results are expressed as the mean ± SD (n≥ 3). * mean P < 0.05 and ** mean P < 0.01
Table 7 Different binding patterns of 22 hit compounds
Binding patterns Hit names Interaction types Pharmacophore interaction regions




metal chelate bonds and hydrogen bonds ZBG domain
2 ZINC03307410, ZINC06415107, ZINC06497704,
ZINC09350495, ZINC12555961, ZINC23141899
metal chelate bonds and hydrogen bonds ZBG domain and linker domain
3 ZINC11325463 metal chelate bonds and hydrogen bonds ZBG domain and cap group domain
4 ZINC03260906, ZINC09715944 metal chelate bonds and hydrogen bonds ZBG domain, linker domain and cap
group domain
5 ZINC02627831, ZINC12581173 hydrogen bonds ZBG domain or linker domain
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(IC50 = 57 μM), but had a less toxic effect on MCF-10A
cells (IC50 = 142 μM). In the HepG2 and L02 cell lines,
ZINC12555961 exhibited nearly the same toxicity, with
IC50 values of 87 and 85 μM, respectively. Furthermore,
in our experiments, ZINC12555961 was more potent than
SAHA in inhibiting the viability of cancer cells (Fig. 4).
The IC50 values of SAHA in HepG2, L02, MDA-MB-231,
and MCF-10A cells were 166 μM, 85 μM, 178 μM, and
59 μM, respectively. The results indicated that
ZINC12555961 has inhibitory activity against all four cells
and displays promising and selective inhibitory activity
against cancer cell viability, ZINC09715944 has inhibitory
activity against HepG2, L02, and MCF-10A cells but not
against MDA-MB-231 cell and does not display selective
inhibitory activity against cancer cell viability, and
zinc02639234 has no inhibitory activity against all four
cells.
As ZINC12555961 could remarkably suppress the
viability of HepG2 and MDA-MB-231 cells, a DAPI
staining assay was performed to determine whether its
inhibitory effect on cell viability is associated with the
induction of cell apoptosis. Fluorescent microscopic
images of DAPI stained nuclei of HepG2 and MDA-
MB-231 cells treated with ZINC12555961 or DMSO
for 48 h are shown in Fig. 5. The concentrations of
zinc12555961 used in HepG2 and MD-231 cells were
90 μM and 60 μM, respectively. Apoptotic nuclei in
both cell lines were split into several nuclear apoptotic
bodies, and apoptotic cells are shown in deep white by
DAPI staining, as indicated by the red arrows (Fig. 5b
and d), whereas cells treated with DMSO exhibited
round intact nuclei. These results indicate that
ZINC12555961 may play an important role in inducing
cancer cell apoptosis.
Fig. 3 Molecular docking results. Docked orientations of a ZINC02639234, b ZINC09715944, and c ZINC12555961. Active site residues are shown
by lines and the metal ion (Zn2+) is shown by a grey sphere. The hydrogen bond network with protein residues and the metal ion is represented
by a yellow dotted line
Table 8 Comparison of the IC50 values of SAHA, ZINC12555961,
ZINC02639234 and ZINC09715944 against the HepG2, L02,
MDA-MB-231 and MCF-10A cell lines
Chemicals IC50(μM)
HepG2 L02 MDA-MB-231 MCF-10A
SAHA 166 ± 9 85 ± 2 178 ± 13 59 ± 10
ZINC12555961 87 ± 10 85 ± 15 57 ± 7 142 ± 17
ZINC02639234 >200 >200 >200 >200
ZINC09715944 157 ± 12 65 ± 3 >200 47 ± 7
Data are expressed as the mean ± SD from at least three independent
experiments
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Flow cytometric analysis with Annexin V-FITC conju-
gated to PI was performed to further examine the effect
of ZINC12555961 on cancer cell apoptosis. HepG2 and
MDA-MB-231 cells were treated with DMSO (90 μM)
or ZINC12555961 (90 μM) for 48 h. Apoptotic cells
were stained and monitored by flow cytometry (Fig. 6).
In both HepG2 and MDA-MB-231 cell lines,
ZINC12555961 significantly induced the late apoptotic
stage. The apoptosis rates of HepG2 cells treated with
DMSO and ZINC12555961 were 5.1 and 47.9 %, re-
spectively, and those of MDA-MB-231 cells treated with
DMSO and ZINC12555961 were 6.4 and 25.2 %,
Fig. 4 Comparison of the cytotoxicity of ZINC12555961 and SAHA against cancer cells and normal cells. a MDA-MB-231 and MCF-10A cells were
treated with 0, 10, 50 and 100 μM SAHA. b HepG2 and L02 cells were treated with 0, 10, 50 and 100 μM SAHA. c MDA-MB-231 and MCF-10A cells
were treated with 0, 10, 50 and 100 μM ZINC12555961. d HepG2 and L02 cells were treated with 0, 10, 50 and 100 μM ZINC12555961. Signifi-
cance was determined by the Student’s t-test. The values represent as the mean ± S.D. * means P < 0.05
Fig. 5 Nuclear morphological changes and apoptotic HepG2 and MDA-MB-231 cells treated with ZINC12555961 (90 μM) and DMSO for 48 h.
Arrows indicate apoptotic nuclei. a HepG2 cells by DAPI staining treated with DMSO. b HepG2 cells by DAPI staining treated with ZINC12555961.
c MDA-MB-231 cells by DAPI staining treated with DMSO. d MDA-MB-231 cells by DAPI staining treated with ZINC12555961
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respectively. ZINC12555961 also affected the early apop-
totic stage in both cell lines. The early apoptosis rates of
the control group vs. the experimental group in HepG2
and MDA-MB-231 cells were 3.5 % vs. 4.5 % and 3.9 %
vs. 8.7 %, respectively. These results indicate that the
rates of apoptosis induced by ZINC12555961 were sig-
nificantly higher than those of the control groups.
ZINC12555961 may play an important role in inducing
cancer cell apoptosis.
As shown above, the effects of ZINC12555961 on
apoptosis, as measured by flow cytometry, do not ex-
plain the decrease of cell viability measured by MTT
assay. This suggests that ZINC12555961 may affect cell
viability through other mechanisms. Therefore, we tested
the effect of ZINC12555961 on cell cycle distribution by
flow cytometric analysis. HepG2 and MDA-MB-231 cells
were treated with ZINC12555961 for 32 and 48 h and
analyzed by flow cytometry (Fig. 7). In the HepG2 cell
line, the percentage of cells in the G1 phase decreased
from 70.3 to 66.4 % in response to ZINC12555961, and
this decrease was accompanied by an increase in the
proportion of cells in the G2 phase from 3.5 to 8.3 %
(Fig. 7a). Similarly, in MDA-MB-231 cells, the percent-
age of cells in the G1 phase decreased from 61.5 to
51.6 % in response to ZINC12555961, and this decrease
was accompanied by an increase in the proportion of
cells in the G2 phase from 12.3 to 24.9 % (Fig. 7b). This
indicates that the inhibitory effect of ZINC12555961 on
the proliferation of HepG2 and MDA-MB-231 cells may
be associated with G2/M phase cell cycle arrest.
Discussions
HDAC enzymes have emerged as exciting and promising
novel targets for the treatment of cancer, diabetes and
other human diseases. HDAC inhibitors, as a new class
of potential therapeutic agents, have attracted a great
deal of interest both for research and clinical applica-
tions. Computer aided drug design (CADD) and virtual
screening have been applied in the development of
new HDAC inhibitors. Many HDAC inhibitors were
designed and synthesized based on CADD approaches
[35–41]. Certain potent HDAC inhibitors with novel
structures were identified by virtual screening approaches
[31, 42, 43]. Vadivelan et al. developed a pharmacophore
model based on common chemical features of HDAC
inhibitors [44]. Melagrakia et al. developed a linear five-
parameter quantitative structure-activity relationship
(QSAR) model of HDAC inhibitors [45]. Xiang et al.
developed a pharmacophore model and three QSAR
models for a series of benzimidazole and imidazole in-
hibitors of HDAC2 [46]. Zhao et al. used a two-step
modeling approach to study the selectivity and activity of
HDAC inhibitors [47]. Thangapandian et al. used pharma-
cophore modeling and molecular docking approaches for
Fig. 6 Quantitative analysis of the effects of ZINC12555961 on the apoptosis of human cancer cell lines. HepG2 cells a and MDA-MB-231 cells
b were treated with DMSO or 90 μM ZINC12555961 for 48 h. Cells were harvested by trypsinization and centrifugation, stained with Annexin
V-FITC and PI, and analyzed by flow cytometry. Representative results are shown
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the identification of potential HDAC8 inhibitors [48].
More recently, Thangapandian et al. used a combined
pharmacophore modeling, molecular docking and mo-
lecular dynamics (MD) simulation approach for the iden-
tification of potential HDAC8 inhibitors [49]. Nair et al.
used a combined pharmacophore modeling, flexible dock-
ing, and three-dimensional QSAR (3D–QSAR) approach
for the identification of benzimidazole and imidazole de-
rivatives [50]. Although these studies did not experimen-
tally validate the activities of their candidate compounds,
their use of virtual screening approaches for HDAC inhib-
itors provides support for further computational and ex-
perimental research. Park et al. identified novel classes of
HDAC inhibitors with new zinc-chelating groups using
docking simulations, and experimentally validated the ac-
tivities of their candidate compounds [42]. Tang et al.
identified three hit compounds using a combinatorial
QSAR screening model based on support vector machine
and k-Nearest Neighbors algorithms, and experimentally
confirmed the inhibitory activities of the compounds
against HDAC1 [31]. Zhang et al. identified a potent
HDAC inhibitor with a novel scaffold using ZBG (zinc-
binding group)-based virtual screening, and experimen-
tally confirmed the inhibitory activities of the compounds
against HDAC8 [43]. In the present study, we developed a
hierarchical virtual screening protocol for the identifi-
cation of potential HDAC inhibitor compounds. The
multistage virtual screening workflow was used to
screen and identify 22 final hit compounds, and the
HDAC inhibitory activities of three of the 22 com-
pounds, namely ZINC12555961, ZINC02639234 and
ZINC09715944, were experimentally validated by in
vitro enzyme inhibition assays. The results confirmed
the efficacy and validity of our screening method. The
three active compounds showed a novel structure that
does not belong to the previously reported four classes
of HDAC inhibitors. All three active hits showed differ-
ent scaffolds, thereby providing wide opportunities for
future HDAC inhibitor design. The novelty of the 22
final hit compounds was assessed using SciFinder
scholar (https://scifinder.cas.org/). The SciFinder re-
sults confirmed that these compounds were not previ-
ously tested for HDAC inhibitory activity.
We further examined the cytotoxicity of the three hit
compounds with HDAC inhibitory activities against the
human normal liver cell line, L02, and the liver cancer
cell line, HepG2, as well as the human breast cancer cell
line, MDA-MB-231, and the human breast epithelial cell
line, MCF-10A. The MTT assay results demonstrated
that the active compound ZINC12555961 could select-
ively suppress the viability of human cancer cell lines
(HepG2 and MDA-MB-231 cells). Staining with DAPI
and Annexin V-FITC/PI flow cytometry assays revealed
that the effect of ZINC12555961 on cancer cell death may
be mediated by the induction of apoptosis and G2/M
phase cell cycle arrest. These results indicate that
ZINC12555961 is a promising HDAC inhibitor and has
anti-tumor potential. Future studies will be aimed at
Fig. 7 Effects of ZINC12555961 on cell cycle progression in cancer cells. HepG2 cells a and MDA-MB-231 cells b were treated with DMSO or
ZINC12555961 for 32 and 48 h. At the end of treatment, cells were trypsinized, incubated with RNase, stained with PI, and analyzed by flow
cytometry. Representative results are shown
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elucidating the molecular mechanisms underlying
ZINC12555961-induced selective cancer cell apoptosis
and evaluating the isoform-selective HDAC inhibitory ef-
fects of ZINC12555961. ZINC12555961-focused virtual
screening will also be further developed in the future.
Conclusions
In conclusion, the study identified three new HDAC in-
hibitors. The new-found HDAC inhibitors are worthy to
further investigations.
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